Abstract Number: 1431 • ACR Convergence 2024
Computational Systems Biology Approach to Unveil Molecular Interactions in Sjogren’s Disease Pathogenesis
Background/Purpose: Sjögren's disease (SjD) presents an unmet medical challenge as there is currently no cure. Despite advances in understanding the immunopathogenesis of SjD, there is…Abstract Number: PP13 • ACR Convergence 2023
My Four Pillars of Wellness: How Sleep, Diet, Exercise and Stress Reduction Enable Me to Define My Life and not let Sjögren’s Define Me
Background/Purpose: Being diagnosed with Sjögren’s has been a life changing event for me.I was diagnosed in 2013 after suffering from various odd ailments. Ultimately, extreme…Abstract Number: 035 • 2020 Pediatric Rheumatology Symposium
The Childhood and Rheumatology Research Alliance Systemic Lupus Erythematosus and Related Disorders Cohort
Background/Purpose: Optimal therapy in childhood onset systemic lupus erythematosus (SLE) lack sufficient data to support clinical decision making. To address this knowledge gap, the Childhood…Abstract Number: 056 • 2020 Pediatric Rheumatology Symposium
Non-criteria Antiphospholipid Antibodies Associated with Pediatric Rheumatic Disease: A Single-Center Case Series
Background/Purpose: Non-criteria antiphospholipid antibodies (NC-aPL) bind molecules such as phosphatidylethanolamine (PE), phosphatidylserine (PS), and prothrombin (Pt), but not the targets of routine antiphospholipid (aPL) testing…Abstract Number: 1455 • 2019 ACR/ARP Annual Meeting
B and T Cell Immunologic Features Associated with Higher Disease Activity Score and Focus Score in Primary Sjögren Syndrome
Background/Purpose: Primary Sjögren syndrome (pSS) is a systemic autoimmune disease with an incompletely understood pathogenesis and heterogenous disease manifestations. Identifying cellular immune changes that may…Abstract Number: 2416 • 2019 ACR/ARP Annual Meeting
ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Associated with Sjögren’s Syndrome
Background/Purpose: ALPN-101 is an Fc fusion protein of a human inducible T cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgDTM) designed to inhibit simultaneously the…Abstract Number: 2435 • 2019 ACR/ARP Annual Meeting
Data Driven Prediction Lymphoma Model and 10-year Overall Survival Rates of a Large Harmonized Cohort of Patients with Primary Sjögren’s Syndrome Associated Lymphomas
Background/Purpose: Non-Hodgkin’s lymphomas (NHLs) may complicate primary Sjögren’s syndrome (pSS) with significant impact on morbidity and mortality among patients. A large cohort of SS associated…Abstract Number: 1458 • 2019 ACR/ARP Annual Meeting
Dual Analysis with Nerve Ultrasound and Skin Biopsy in Painful Neuropathy Associated with Sjögren’s Syndrome
Background/Purpose: 6% of primary Sjögren's syndrome (pSS) patients manifests as various forms of neuropathies including painful sensory neuropathy (PSN), which can be treatable with immunomodulatory drugs such…Abstract Number: 2417 • 2019 ACR/ARP Annual Meeting
A Phase 2a Study of MEDI5872 (AMG557), a Fully Human Anti-ICOS Ligand Monoclonal Antibody in Patients with Primary Sjögren’s Syndrome
Background/Purpose: The interaction of inducible T cell costimulatory ligand (ICOSL) and the ICOS receptor is key in the pathogenesis of primary Sjögren’s syndrome (pSS). MEDI5872…Abstract Number: 2436 • 2019 ACR/ARP Annual Meeting
The Salivary Glands as the Key Site of Inflammation and Lymphoproliferation Leading to Lymphoma in Primary Sjögren’s Syndrome: Relevance for Dedicated Scoring, Biomarker Development and Lymphoma Prevention
Background/Purpose: Since the risk of B-cell non-Hodgkin’s lymphoma (NHL) evolution is increased in primary Sjögren’s syndrome (pSS), its prevention represents a relevant therapeutic end-point. A…Abstract Number: 1459 • 2019 ACR/ARP Annual Meeting
Systemic Manifestations of Primary Sjögren Syndrome out of the ESSDAI Classification: Prevalence and Clinical Relevance in a Large International, Multi-ethnic Cohort of Patients
Background/Purpose: To analyse the frequency and characterize the systemic presentation of primary Sjögren syndrome (SjS) out of the ESSDAI classification in a large international, multi-ethnic…Abstract Number: 2418 • 2019 ACR/ARP Annual Meeting
Tofacitinib Inhibits Increased Inflammatory Marker Expression in a Human Salivary Cell Line Deficient in Autophagy: A Model of Sjögren’s Syndrome
Background/Purpose: Sjögren’s syndrome (SS) is an immune-mediated exocrinopathy, where defects in autophagy could contribute to the pathogenesis. Minor labial salivary glands (MLSG) of primary SS…Abstract Number: 2437 • 2019 ACR/ARP Annual Meeting
Autoantibodies from Sjögren’s Syndrome Enhance NLRP3 Inflammasome Activation and IL-18 Production in Human Salivary Gland Cell Line A-253
Background/Purpose: Primary Sjögren's syndrome (SS) is a chronic autoimmune epithelitis characterized by the presence of autoantibodies against SS-related antigen A (SSA) and lymphocytic infiltration of…Abstract Number: 1462 • 2019 ACR/ARP Annual Meeting
Pathogenesis of Vaginal Dryness in Primary Sjögren’s Syndrome: A Histopathological Case-control Study
Background/Purpose: Women with primary Sjögren’s syndrome (pSS) often experience vaginal dryness, but the pathogenesis of this symptom is unknown. Previously, we reported impaired vaginal health…Abstract Number: 2419 • 2019 ACR/ARP Annual Meeting
An ex-vivo Assay to Evaluate the Efficacy of Different Treatments for Inhibiting B Lymphocytes Activation by Salivary Gland Epithelial Cells in Sjögren’s Syndrome
Background/Purpose: Primary Sjögren's syndrome (pSS) is an auto-immune disorder characterized by a chronic hyperactivation of B lymphocytes. We previously showed that salivary gland epithelial cells…
- 1
- 2
- 3
- …
- 26
- Next Page »